President Donald Trump has called the antibody cocktail he received to debar the coronavirus “a cure,” but the chief executive of Regeneron Pharmaceuticals Inc. said Sunday that Trump’s case is simply “a case of 1 ,” and therefore the treatment still needs more testing before its efficacy is understood .

In an interview with CBS News’ “Face the state ,” Regeneron REGN, +0.36% CEO Leonard Schleifer — whose company made the experimental highly active antiretroviral therapy that apparently helped Trump — warned against jumping to conclusions.

“So the president’s case may be a case of 1 , and that’s what we call a case report, and it’s evidence of what’s happening, but it’s quite the weakest evidence that you simply can get,” he said, consistent with a CBS News transcript.

Schleifer said that while Trump’s case had “some very interesting aspects,” like his age and risk factors, his results are “just low down on the evidence scale that we actually need.”

“The real evidence has got to come — about how good a drug is and what it’ll do on the average has got to come from these large clinical trials, these randomized clinical trials, which are the gold standard. and people are ongoing,” he said.

Trump’s doctors said Saturday the president was not in danger of spreading the virus, and Trump told Fox News on Sunday that he’s now resistant to COVID-19.

Schleifer was cautious therein assessment also . While saying the Regeneron drug “does” create immunity, it’s not known how long it lasts. “Could be months, might be years,” he said. “If you catch on in our vial, if you’ll , that’s likely to last you for months.”

Schleifer also addressed Trump’s involve the Regeneron drug to be distributed for free of charge to all or any who need it. The U.S. government has bought 300,000 doses for $450 million, which can be distributed for free of charge , and Schleifer said there are already 50,000 doses able to go.

Still, with the U.S. averaging nearly 50,000 new cases each day last week, “It’s not enough,” Schleifer said, adding that if the drug is found to be effective, other drug makers are going to be needed to dig in on production. “Regeneron can’t do that alone. we’d like the whole industry,” he said.

LEAVE A REPLY

Please enter your comment!
Please enter your name here